Bivara 25 FC Tablet

About Bivara 25 FC Tablet

Bivara 25 FC is a tablet made by Advanced Chemical Industries PLC. It contains brivaracetam 25 mg and is classed as an add-on anti-epileptic medicine.

There are 10 brands of Brivaracetam listed in Bangladesh.

What is Bivara 25 FC Tablet?

Bivara 25 FC is a tablet from Advanced Chemical Industries PLC that contains brivaracetam 25 mg. It belongs to the group of adjunct anti-epileptic drugs, which means it is used alongside other seizure medicines rather than on its own. Brivaracetam acts on a brain protein called SV2A, and it is also thought to affect sodium channels; how exactly it controls seizures is not fully understood. It is prescribed for partial-onset seizures. Only a qualified doctor can decide whether it suits a particular person, and the dose and course are set by the doctor.

Uses of Bivara 25 FC

Bivara 25 FC is used to treat partial-onset seizures, a type of epilepsy in which seizures begin in one part of the brain. It is given as an add-on to other anti-epileptic treatment. It is intended for adults and for children from four years of age, with the doctor choosing the appropriate regimen. It is not a general treatment for all seizure types, so the doctor confirms whether it fits the patient's condition.

How to use Bivara 25 FC

Bivara 25 FC is taken by mouth as a tablet. The doctor decides the dose, how often it is taken and how long the course lasts, and may adjust it depending on how the patient responds and tolerates the medicine. Swallow the tablet as your doctor or pharmacist advises. Do not stop the medicine on your own, because stopping anti-epileptic treatment suddenly can be harmful. Ask your doctor or pharmacist if you are unsure how to take it.

Side effects of Bivara 25 FC

The most common side effects reported with brivaracetam are sleepiness or sedation, dizziness, tiredness, and nausea or vomiting. Because sleepiness and fatigue can occur, do not drive or operate machinery until you know how the medicine affects you. Some people may have changes in mood or behaviour. Seek medical care straight away if you have a serious allergic reaction such as breathing difficulty or swelling. Tell your doctor about any side effect that bothers you.

Safety and precautions

Do not take Bivara 25 FC if you are allergic to brivaracetam or to any other ingredient in the tablet. Tell your doctor before starting if you are pregnant, planning a pregnancy or breastfeeding, because information on its use in these situations is limited. The doctor will also want to monitor mood, behaviour, sleepiness and any allergic signs during treatment. People with kidney or liver problems, or anyone taking other medicines, should ask the doctor first. Never stop the medicine suddenly without medical advice.

Frequently asked questions

What kind of medicine is Bivara 25 FC and what is it used for?

It is an add-on anti-epileptic tablet containing brivaracetam 25 mg, made by Advanced Chemical Industries PLC. It is used for partial-onset seizures alongside other seizure medicines. The doctor decides whether it is suitable and sets the dose and course.

Who should avoid Bivara 25 FC or ask the doctor first?

Anyone allergic to brivaracetam or to the tablet's other ingredients should not take it. People who are pregnant, planning pregnancy or breastfeeding, and those with other health conditions or other medicines, should speak to the doctor before starting. The doctor will decide if it is appropriate.

Which medicines may interact with Bivara 25 FC?

Interactions have been noted with rifampin, carbamazepine, phenytoin and levetiracetam. The doctor may adjust doses or monitor levels when these are taken together. Always tell your doctor and pharmacist about every medicine you use, including those bought without a prescription, before starting treatment.

Can I stop taking Bivara 25 FC on my own?

No. Anti-epileptic medicines should not be stopped suddenly, as this can be harmful. The doctor decides how and when to change or stop treatment. Speak to your doctor or pharmacist if you have concerns about your medicine or how it is working for you.

Indications

Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of Brivaracetam injection in pediatric patients has not been established, Brivaracetam injection is indicated for the treatment of partial-onset seizures only in adult patients (16 years of age and older).

Pharmacology

The precise mechanism by which Brivaracetam exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect.

Brivaracetam binds SV2A with high affinity. SV2A is known to play a role in epileptogenesis through modulation of synaptic GABA release. It is thought that brivaracetam exerts its anti-epileptogenic effects through its binding to SV2A. Brivaracetam is also known to inhibit Na+ channels which may also contribute to its anti-epileptogenic action

Dosage & Administration

Adults (16 Years and older): The recommended starting dosage for monotherapy or adjunctive therapy is 50 mg twice daily (100 mg per day).

Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day).

Pediatric Patients (4 Years to less than 16 Years): The recommended dosage is based on body weight and is administered orally twice daily

Injection: for intravenous and adult use only when oral administration is temporarily not feasible; dosing is the same as oral regimen.

Interaction

Rifampin: Because of decreased concentrations, increasing Brivaracetam dosage in patients on concomitant rifampin is recommended.

Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant Brivaracetam.

Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant Brivaracetam.

Levetiracetam: Brivaracetam had no added therapeutic benefit when co-administered with levetiracetam.

Contraindications

Hypersensitivity to brivaracetam or any of the inactive ingredients in Brivaracetam

Side Effects

Most common adverse reactions (at least 5% for Brivaracetam and at least 2% more frequently than placebo) are somnolence/sedation, dizziness, fatigue, and nausea or vomiting.

Pregnancy & Lactation

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as Brivaracetam, during pregnancy. No data are available regarding the presence of brivaracetam in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Studies in lactating rats have shown excretion of brivaracetam or metabolites in milk

Precautions & Warnings

Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and ideation.

Neurological Adverse Reactions: Monitor for somnolence and fatigue, and advise patients not to drive or operate machinery until they have gained sufficient experience on Brivaracetam.

Psychiatric Adverse Reactions: Behavioral reactions including psychotic symptoms, irritability, depression, aggressive behavior, and anxiety; monitor patients for symptoms.

Hypersensitivity: Bronchospasm and Angioedema: Advise patients to seek immediate medical care. Discontinue and do not restart Brivaracetam if hypersensitivity occurs. 

Withdrawal of Antiepileptic Drugs: Brivaracetam should be gradually withdrawn.

Storage Conditions

Store at 25°C; excursions permitted between 15°C to 30°C

Alternative brands of Brivaracetam

Other brands with the same generic name, cheapest first.

Bivara Oral Solution

10 mg/ml

Brivaracetam

Advanced Chemical Industries PLC

Price not listed

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.